James Mugford, MD
Internal Medicine · Indian Orchard, MANPI 1760582019
Payments from drug & device makers
Across 665 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$1K
- Boehringer Ingelheim$835
- GSK$662
- plus $4K from 28 others
What the payments were for
- Food & beverage$11,69999%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 116 | $2,302 |
| Novo Nordisk | 69 | $1,275 |
| Lilly USA, LLC | 66 | $1,142 |
| Pfizer | 88 | $1,126 |
| Boehringer Ingelheim | 49 | $835 |
| GSK | 40 | $662 |
| Abbott | 28 | $588 |
| Johnson & Johnson | 31 | $504 |
| Merck | 29 | $488 |
| Exact Sciences | 22 | $403 |
| Novartis | 20 | $360 |
| E.r. Squibb & Sons, L.L.C. | 20 | $353 |
| AbbVie(2 entities) | 19 | $353 |
| Sanofi-aventis U.S. LLC | 14 | $293 |
| Astellas Pharma US Inc | 10 | $280 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $151 |
| Dexcom, Inc. | 4 | $93 |
| Baxter Healthcare | 2 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Eisai Inc. | 2 | $50 |
| Amarin Pharma, Inc. | 3 | $48 |
| Tactile Systems Technology Inc | 2 | $34 |
| Bayer | 1 | $32 |
| Corium, LLC | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Valeritas, Inc. | 1 | $23 |
| Vertex | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Alk-abello, Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $13 |
How this compares
$11,813 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 73 | $82,907 |
| OzempicSemaglutide | 54 | $60,217 |
| JardianceEmpagliflozin | 51 | $54,720 |
| EliquisApixaban | 56 | $40,529 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $33,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $28,232 |
| MounjaroTirzepatide | 26 | $24,835 |
| TrulicityDulaglutide | 16 | $24,155 |
| MyrbetriqMirabegron | 19 | $10,896 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $10,370 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $8,250 |
| Atorvastatin Calcium | 489 | $5,462 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,884 |
| Rosuvastatin Calcium | 142 | $3,720 |
| LivaloPitavastatin Calcium | 11 | $3,636 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $2,302 | $116,713108 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $835 | $65,09164 claims |
| Novo NordiskOzempic | $1,275 | $60,21754 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,142 | $48,99042 claims |
| PfizerEliquis | $1,126 | $40,52956 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $662 | $33,11633 claims |
| Astellas Pharma US IncMyrbetriq | $280 | $10,89619 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $26 | $3,63611 claims |
| AbbVieSynthroid | $353 | $78016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Indian Orchard
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.